FASN and cancer: Given that elevated fatty acid biosynthesis and increased expression of lipogenic enzymes such as FASN and ACC have been identified as a near-universal feature of human cancers, therapeutic approaches have been developed to target the key lipogenic enzymes, such as ACC, FASN and stearoyl-CoA desaturase 1 (Baenke et al., 2013; Cheng et al., 2018; Guo et al., 2014; Menendez and Lupu, 2007; Shimano and Sato, 2017).